Sera Prognostics Reports Q4/FY25 Results, Highlights Positive Clinical Data & Extends Cash Runway to 2028

summarizeSummary

Sera Prognostics announced its Q4 and full-year 2025 financial results, reporting continued losses but a strong cash position extending its runway through 2028, alongside positive clinical data and commercial progress for its PreTRM® test.

check_boxKey Events

• Q4 and Full-Year 2025 Financial Results

  Reported Q4 2025 revenue of $10,000 and a net loss of $7.9 million. Full-year 2025 revenue was $81,000 with a net loss of $31.9 million, showing slight improvement in net loss year-over-year.

• Extended Cash Runway

  Ended 2025 with $95.8 million in cash, cash equivalents, and available-for-sale securities, which is expected to fund operations through 2028 following a $57.5 million financing in February 2025.

• Landmark Clinical Data Publication

  The PRIME Study, a randomized controlled trial, was published in January 2026, demonstrating the PreTRM® Blood Test reduces earliest preterm births and newborn complications.

• Commercial Expansion

  Advanced discussions with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption and expanded the U.S. commercial organization.

auto_awesomeAnalysis

This filing provides the detailed Q4 and full-year 2025 financial results, which show continued low revenue and significant net losses. However, the company's cash position of $95.8 million, secured by a February 2025 financing, is projected to fund operations through 2028. This extended cash runway is a critical positive for a company in its commercialization phase, mitigating immediate liquidity concerns. The report also highlights the publication of the landmark PRIME Study, demonstrating the efficacy of its PreTRM® test, and significant commercial engagement, which are key drivers for future growth and adoption. Investors should monitor the conversion of these clinical and commercial milestones into revenue growth.